Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultralife (ULBI) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Ultralife (ULBI) over the last 14 years, with Q3 2025 value amounting to $987097.0.

  • Ultralife's Gains from Investment Securities rose 1413.45% to $987097.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $987097.0, marking a year-over-year increase of 1413.45%. This contributed to the annual value of $1.1 million for FY2024, which is 1152.72% down from last year.
  • As of Q3 2025, Ultralife's Gains from Investment Securities stood at $987097.0, which was up 1413.45% from $998064.0 recorded in Q2 2025.
  • In the past 5 years, Ultralife's Gains from Investment Securities registered a high of $1.4 million during Q1 2023, and its lowest value of $58000.0 during Q1 2021.
  • For the 4-year period, Ultralife's Gains from Investment Securities averaged around $967424.4, with its median value being $1.1 million (2021).
  • The largest annual percentage gain for Ultralife's Gains from Investment Securities in the last 5 years was 62500.0% (2021), contrasted with its biggest fall of 3906.09% (2021).
  • Quarter analysis of 4 years shows Ultralife's Gains from Investment Securities stood at $1.1 million in 2021, then plummeted by 47.78% to $556000.0 in 2023, then skyrocketed by 99.0% to $1.1 million in 2024, then decreased by 10.79% to $987097.0 in 2025.
  • Its Gains from Investment Securities was $987097.0 in Q3 2025, compared to $998064.0 in Q2 2025 and $1.1 million in Q1 2025.